Table 2.
Precancer (N = 37) | OSCC (N = 124) | Recurrence (N = 21) | P | |
---|---|---|---|---|
Spontaneous intensity | 26.73 ± 15.78 | 29.53 ± 14.80 | 33.53 ± 17.53 | P1 = 0.693 P2 = 0.560 |
Functional intensity | 28.47 ± 16.23 | 32.73 ± 16.34 | 37.67 ± 17.19 | P1 = 0.561 P2 = 0.430 |
Spontaneous sharpness | 10.40 ± 8.28 | 15.60 ± 12.85 | 36.40 ± 15.87 | P1 = 0.278 P2 = 0.000 |
Functional sharpness | 14.27 ± 9.29 | 20.87 ± 13.03 | 38.87 ± 16.47 | P1 = 0.225 P2 = 0.002 |
Spontaneous aching | 10.40 ± 10.72 | 28.33 ± 14.56 | 35.73 ± 13.06 | P1 = 0.001 P2 = 0.129 |
Functional aching | 14.67 ± 11.91 | 33.33 ± 13.54 | 40.93 ± 14.48 | P1 = 0.001 P2 = 0.197 |
Sensitivity to touch | 24.67 ± 16.14 | 44.87 ± 21.13 | 60.87 ± 19.72 | P1 = 0.009 P2 = 0.027 |
Functional restriction | 27.20 ± 15.52 | 46.20 ± 16.20 | 59.93 ± 10.81 | P1 = 0.001 P2 = 0.014 |
P1 = recurrence group vs. pre-cancer group. P2 = recurrence group vs. OSSC group.